Physician profile
Michael T Cox
NPI 1356305197
$3,116.73
in general payments reported to CMS, 2019-2025
34 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $285 · 2021: $632 · 2022: $779 · 2023: $518 · 2024: $195 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,281.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $194.24 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Atricure, INC. | $176.25 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Sunovion Pharmaceuticals INC. | $167.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $134.09 | 2021-2025 | Breztri, Airsupra |
| Xeris Pharmaceuticals, INC. | $96.54 | 2021-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.24 | 2019-2024 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.66 | 2022-2025 | Xifaxan, Trulance |
| Abbvie INC. | $71.60 | 2021-2022 | |
| Lilly USA, LLC | $69.30 | 2019-2022 | |
| Astellas Pharma US INC | $68.74 | 2019 | |
| Glaxosmithkline, LLC. | $61.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.59 | 2019 | |
| Amarin Pharma, INC. | $48.46 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $42.39 | 2023-2024 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $38.84 | 2019 | |
| Merck Sharp & Dohme LLC | $34.84 | 2019-2021 | |
| Cranial Technologies, INC | $33.79 | 2022-2023 | Doc Band |
| Pfizer INC. | $32.87 | 2019 | |
| Insulet Corporation | $32.41 | 2023 | Omnipod |
| Janssen Pharmaceuticals, INC | $31.37 | 2021-2022 | |
| Eisai INC. | $30.80 | 2020-2022 | |
| Amgen INC. | $30.76 | 2023-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $26.27 | 2023 | Glassia |
| Biohaven Pharmaceutical Holding Company LTD. | $25.87 | 2022 | |
| Sanofi Pasteur INC. | $25.66 | 2020 | |
| Corium, LLC | $22.36 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.20 | 2022 | |
| Boston Scientific Corporation | $19.52 | 2022 | |
| Sk Life Science, INC. | $19.28 | 2021 | |
| Daiichi Sankyo INC. | $19.27 | 2021 | |
| Evoke Pharma, INC. | $16.45 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.76 | 2022 | |
| Cmp Pharma, INC. | $13.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.